This rapid response report from the Canadian Agency for Drugs and Technologies in Health (CADTH) reviews the clinical effectiveness of botulinum toxin A for reduction in pain and improvement of functioning in patients with migraine headache

It found that, ‘the evidence is inconclusive regarding the clinical effectiveness of botulinum toxin A for reduction in pain and improvement of functioning in patients with migraine headache’.

The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources and a summary of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information and health care considerations